The fully human, monoclonal, IL-13 blocker tralokinumab showed to be highly effective in patients with moderate-to-severe atopic dermatitis (AD) . Dysregulation of cell-mediated immune response plays a key role in the pathogenesis of AD. As a result, IL-13 and other type 2 cytokines are overexpressed.
The presented phase 2b trial included 204 adult patients with moderate-to-severe AD. For 12 weeks, 3 randomised groups of study subjects were treated with either 45 mg, 150 mg, or 300 mg of tralokinumab every second week, with a fourth group receiving a placebo. All patients were on a background treatment with topical corticosteroids (WHO class 3). These steroids were applied ≥1 time daily during 2 weeks before receiving tralokinumab, and, if necessary, throughout the rest of the trial. Efficacy was assessed by the percentage of subjects reaching an Investigator’s Global Assessment (IGA) score of 0 or 1, corresponding to clear or almost clear skin with a ≥...
Please login to read the full text of the article.
If you have no account yet, please register now.
« New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials Next Article
Thicker AK lesions benefit from laser pretreatment with high channel density »